OBJECTIVE: Despite the lack of any scientific data, many ART programs split the daily gonadotropin dose during ovarian stimulation, while others give the entire dose during a single administration, usually at night. DESIGN: Prospective randomized. PATIENT(S): 213 women undergoing IVF/ICSI cycles at a single private ART center. INTERVENTION(S): Gonadotropin administration once daily compared to twice daily. MAIN OUTCOME MEASURE(S): Gonadotropin usage, clinical and ongoing PR RESULTS: There were 110 women in the once daily compared to 103 in the twice daily arm. All cycles were blastocyst transfers. There was a significantly lower FSH use in the once daily arm compared to the twice daily arm (1507.5 ± 517.5 IU vs. 1702.5 ± 622.5, P = 0.015), and a trend towards lower hMG use in the once daily arm (1342.5 ± 562.5 IU vs. 1462.5 ± 645.0, P = 0.15), without compromising clinical pregnancy rate (PR) (71.8% vs. 70.9%, P = NS) or delivery/ongoing PR (58.2% vs. 62.1%, P = NS). There were no differences in age, body mass index (BMI), peak estradiol, peak progesterone, retrieved oocytes, fertilized oocytes, number of ET, or PR. CONCLUSIONS: Once daily administration is associated with lower gonadotropin usage without compromising success rates.
RCT Entities:
OBJECTIVE: Despite the lack of any scientific data, many ART programs split the daily gonadotropin dose during ovarian stimulation, while others give the entire dose during a single administration, usually at night. DESIGN: Prospective randomized. PATIENT(S): 213 women undergoing IVF/ICSI cycles at a single private ART center. INTERVENTION(S): Gonadotropin administration once daily compared to twice daily. MAIN OUTCOME MEASURE(S): Gonadotropin usage, clinical and ongoing PR RESULTS: There were 110 women in the once daily compared to 103 in the twice daily arm. All cycles were blastocyst transfers. There was a significantly lower FSH use in the once daily arm compared to the twice daily arm (1507.5 ± 517.5 IU vs. 1702.5 ± 622.5, P = 0.015), and a trend towards lower hMG use in the once daily arm (1342.5 ± 562.5 IU vs. 1462.5 ± 645.0, P = 0.15), without compromising clinical pregnancy rate (PR) (71.8% vs. 70.9%, P = NS) or delivery/ongoing PR (58.2% vs. 62.1%, P = NS). There were no differences in age, body mass index (BMI), peak estradiol, peak progesterone, retrieved oocytes, fertilized oocytes, number of ET, or PR. CONCLUSIONS: Once daily administration is associated with lower gonadotropin usage without compromising success rates.
Authors: William R Keye; Richard P Marrs; Jerome H Check; Vicki Schnell; Mark Surrey; Dennis C Marshall Journal: Fertil Steril Date: 2004-08 Impact factor: 7.329
Authors: Kevin J Doody; Vicki L Schnell; Russell A Foulk; Charles E Miller; Bradford A Kolb; Emily J Blake; Vladimir I Yankov Journal: Fertil Steril Date: 2008-04-18 Impact factor: 7.329